Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer

医学 胰腺癌 肺癌 内科学 肿瘤科 癌症 胰腺疾病 腺癌 肺 疾病
作者
Wungki Park,Anup Kasi,Alexander I. Spira,Luis Paz-Ares Rodríguez,Benjamin O. Herzberg,Meredith S. Pelster,Anthony W. Tolcher,Yasutoshi Kuboki,Shigehisa Kitano,Hirokazu Shoji,J. Wang,Jordan D. Berlin,Antoine Hollebecque,Patricia Mucci LoRusso,Christos K Fountzilas,Philippe Alexandre Cassier,Tomohiro Nishina,Daisuke Sakai,Chiaki Inagaki,Daniel Morgensztern
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:394 (14): 1409-1420 被引量:53
标识
DOI:10.1056/nejmoa2600752
摘要

BACKGROUND: p.G12D variant occurs in 5% of patients with non-small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, but no targeted therapies directed against this variant are currently approved for clinical use. Setidegrasib (ASP3082) is a first-in-class KRAS G12D-targeted protein degrader. METHODS: p.G12D variants. The primary objectives were to evaluate the safety profile, as indicated by dose-limiting toxic effects and adverse events (the primary end points), and to determine the phase 2 dose. Setidegrasib was administered intravenously once weekly at doses of 10 to 800 mg. RESULTS: Overall, 203 patients were enrolled. Among the 76 patients who received setidegrasib at a dose of 600 mg, which was ultimately selected as the phase 2 dose, adverse events occurred during treatment in all the patients, with events of grade 3 or higher in 42%. Treatment-related adverse events occurred in 93% of the patients; the most common were transient infusion-related reactions (in 80%) and nausea (in 30%). Adverse events led to discontinuation in 2 patients. Among the 45 patients with NSCLC who received the 600-mg dose, 36% (95% confidence interval [CI], 22 to 51) had a partial response, the median progression-free survival was 8.3 months (95% CI, 4.1 to could not be estimated), and the estimated 12-month overall survival was 59% (95% CI, 40 to 74). Among the 21 patients with metastatic pancreatic ductal adenocarcinoma who received the 600-mg dose as second- or third-line treatment (of whom 67% received setidegrasib as third-line treatment), 24% (95% CI, 8 to 47) had a response, the median progression-free survival was 3.0 months (95% CI, 1.4 to 6.9), and the median overall survival was 10.3 months (95% CI, 4.2 to 13.0). CONCLUSIONS: p.G12D-mutated NSCLC or pancreatic ductal adenocarcinoma. (Funded by Astellas Pharma; ClinicalTrials.gov number, NCT05382559.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
MCS完成签到,获得积分10
刚刚
开朗的如蓉完成签到,获得积分10
1秒前
乐呵的葫芦娃完成签到,获得积分10
1秒前
龙龙发布了新的文献求助10
1秒前
思絮完成签到 ,获得积分10
1秒前
宅宅发布了新的文献求助10
1秒前
LEE完成签到,获得积分10
2秒前
桐桐的应助被momo采纳,获得10
2秒前
2秒前
onliwan完成签到 ,获得积分10
2秒前
阿晃完成签到,获得积分20
2秒前
红炉点血发布了新的文献求助10
2秒前
共享精神的应助被Michael_li采纳,获得10
3秒前
Yuther完成签到 ,获得积分10
3秒前
Sissi完成签到,获得积分10
3秒前
Lifel完成签到 ,获得积分10
4秒前
hoenglam发布了新的文献求助30
4秒前
糖糖糖唐发布了新的文献求助10
5秒前
honglingjing发布了新的文献求助10
5秒前
冬阳完成签到,获得积分10
5秒前
上官完成签到,获得积分10
5秒前
乔乔完成签到,获得积分10
5秒前
英俊亦巧完成签到,获得积分10
6秒前
Ai完成签到,获得积分10
6秒前
6秒前
小太阳完成签到,获得积分10
7秒前
8秒前
小鱼儿完成签到,获得积分10
8秒前
8秒前
ssss发布了新的文献求助10
9秒前
tszjw168发布了新的文献求助10
9秒前
9秒前
xiaona完成签到,获得积分10
9秒前
Ting完成签到,获得积分10
9秒前
周123456完成签到,获得积分10
9秒前
欢喜大白菜真实的钥匙完成签到 ,获得积分10
9秒前
cr7完成签到,获得积分10
10秒前
科研通AI6.3的应助被Ho采纳,获得10
10秒前
11秒前
小七完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180111
求助须知:如何正确求助?哪些是违规求助? 9570235
关于积分的说明 21809184
捐赠科研通 7776198
什么是DOI,文献DOI怎么找? 3433262
关于科研通互助平台的介绍 2557463
邀请新用户注册赠送积分活动 2479039